Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the role of NINJ1 in hepatic ischemia-reperfusion injury

EF 2021-22

Résumé
For many patients with end-stage liver disease, liver transplantation is their only curative treatment option. Unfortunately, hepatic ischemia-reperfusion injury (IRI), inherent to liver transplantation, contributes to adverse transplantation outcomes such as graft dysfunction, rejection, and patient mortality. The temporary ischemic state of the extracted organ and the sudden restoration of blood flow to the organ following transplantation into the recipient ultimately lead to cell death and an injurious inflammatory response in the liver. This damaging inflammatory response in hepatic IRI is driven by lytic cell death pathways that result in cell rupture and consequent release of proinflammatory molecules. Recently, ninjurin-1 (NINJ1), a protein expressed in liver cells, has been identified as necessary for cells to rupture in lytic cell death. Inhibiting NINJ1 to block cell rupture and subsequent release of proinflammatory molecules can potentially reduce the inflammatory response in hepatic IRI. Therefore, my central hypothesis is that inhibiting NINJ1 will prevent liver cell death and protect the liver against the damaging effects of IRI. To test this hypothesis, I will be using a mouse model of hepatic IRI. Specifically, I will be assessing whether the pharmacologic inhibition or genetic deletion of NINJ1 in mice during hepatic IRI can reduce inflammation and injury in the liver. The results from this project can potentially identify NINJ1 as a promising therapeutic target for protecting the liver against hepatic IRI during transplantation. Additionally, if inhibiting NINJ1 can protect the liver from IRI, marginal donor organs that are ineligible for donation due to their susceptibility to IRI can potentially be included to expand the limited donor organ pool.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466692
Name
Zhao Yixuan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of NINJ1 in hepatic ischemia-reperfusion injury
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Inflammasomes; Ischemia Reperfusion Injury; Liver Transplantation; Lytic Cell Death Pathways; Pyroptosis
Abstract
For many patients with end-stage liver disease, liver transplantation is their only curative treatment option. Unfortunately, hepatic ischemia-reperfusion injury (IRI), inherent to liver transplantation, contributes to adverse transplantation outcomes such as graft dysfunction, rejection, and patient mortality. The temporary ischemic state of the extracted organ and the sudden restoration of blood flow to the organ following transplantation into the recipient ultimately lead to cell death and an injurious inflammatory response in the liver. This damaging inflammatory response in hepatic IRI is driven by lytic cell death pathways that result in cell rupture and consequent release of proinflammatory molecules. Recently, ninjurin-1 (NINJ1), a protein expressed in liver cells, has been identified as necessary for cells to rupture in lytic cell death. Inhibiting NINJ1 to block cell rupture and subsequent release of proinflammatory molecules can potentially reduce the inflammatory response in hepatic IRI. Therefore, my central hypothesis is that inhibiting NINJ1 will prevent liver cell death and protect the liver against the damaging effects of IRI. To test this hypothesis, I will be using a mouse model of hepatic IRI. Specifically, I will be assessing whether the pharmacologic inhibition or genetic deletion of NINJ1 in mice during hepatic IRI can reduce inflammation and injury in the liver. The results from this project can potentially identify NINJ1 as a promising therapeutic target for protecting the liver against hepatic IRI during transplantation. Additionally, if inhibiting NINJ1 can protect the liver from IRI, marginal donor organs that are ineligible for donation due to their susceptibility to IRI can potentially be included to expand the limited donor organ pool.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhao, Yixuan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~